Transenterix Inc (NASDAQ:TRXC) shares traded up 21.1% during trading on Monday . The stock traded as high as $3.03 and last traded at $2.87. 18,594,533 shares were traded during mid-day trading, an increase of 163% from the average session volume of 7,070,060 shares. The stock had previously closed at $2.37.
TRXC has been the topic of several recent analyst reports. Zacks Investment Research cut Transenterix from a “buy” rating to a “sell” rating in a report on Tuesday, August 8th. Stifel Nicolaus restated a “buy” rating and set a $4.00 price target (up from $3.75) on shares of Transenterix in a research report on Monday. Finally, Ladenburg Thalmann Financial Services set a $5.00 price target on Transenterix and gave the stock a “buy” rating in a research report on Friday, October 20th.
The firm’s market capitalization is $439.67 million. The firm has a 50-day moving average of $1.98 and a 200-day moving average of $1.04.
In other news, insider Todd Pope sold 600,000 shares of the firm’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $3.68, for a total value of $2,208,000.00. Following the completion of the sale, the insider now owns 462,644 shares of the company’s stock, valued at approximately $1,702,529.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Several institutional investors have recently bought and sold shares of TRXC. LMR Partners LLP acquired a new stake in shares of Transenterix in the 2nd quarter worth $189,000. Global X Management Co. LLC boosted its position in shares of Transenterix by 238.3% in the 2nd quarter. Global X Management Co. LLC now owns 331,075 shares of the company’s stock worth $235,000 after purchasing an additional 233,213 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Transenterix by 17.1% in the 2nd quarter. Royal Bank of Canada now owns 418,867 shares of the company’s stock worth $298,000 after purchasing an additional 61,034 shares in the last quarter. UBS Oconnor LLC acquired a new stake in shares of Transenterix in the 2nd quarter worth $390,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Transenterix by 7,137.7% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,203,199 shares of the company’s stock worth $854,000 after purchasing an additional 1,186,575 shares in the last quarter.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
What are top analysts saying about Transenterix Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Transenterix Inc and related companies.